Skip to main content
SpringerLink
Log in

Vorteil durch Nivolumab beim metastasierten Melanom

  • Literatur kompakt
  • Published:
hautnah dermatologie Aims and scope

Nivolumab blockiert den Rezeptor PD-1 (Programmed cell death protein 1) und steigert dadurch die Aktivität der krebsspezifischen T-Zellen. Die Wirksamkeit bei therapienaiven Patienten mit metastasiertem Melanom ohne BRAF-Mutation prüfte die Phase-III-Studie CheckMate-066.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Robert C et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. New Engl J Med 2014; doi: 10.1056/NEJMoa1412082

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Peter Leiner

Authors
  1. Peter Leiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leiner, P. Vorteil durch Nivolumab beim metastasierten Melanom. hautnah dermatologie 31, 19 (2015). https://doi.org/10.1007/s15012-015-1745-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-015-1745-8

Search

Navigation